Royalty Report: Assay, Diagnostic, Medical – Collection: 286051

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Assay
  • Diagnostic
  • Medical
  • Proteins
  • Drugs
  • Immune
  • Cancer
  • Technical Know How
  • Antibody
  • Supply
  • Genome
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 286051

License Grant
The Licensor of England grants the exclusive rights to make have made use and sell Products and to practice the methods described in the said Patent Rights to conduct clinical assays.

Licensor shall promptly after the date hereof disclose to Licensee all Proprietary Information owned or controlled by Licensor which is reasonably necessary to enable Licensee to make have made use and sell Products and to apply Chemiluminescence Technology to clinical diagnostic assay products and procedures and Licensor grants to Licensee the right and license to use such Proprietary Information to make or have made Products in the Countries identified and to use and sell Products and to perform clinical assays throughout the world.

Licensor agrees to grant to Licensee an exclusive license under all patent rights inventions know-how and proprietary information that it may hereafter come to own or control or shall have the right to sublicense during the Term of this Agreement and which cover or relate to improvements to Licensors licensed Patent Rights Products or to the assays agreed by Licensor and Licensee to enable Licensee to use such Patent rights inventions know-how and Proprietary Information to improve such Products and assays.

If Licensor develops new diagnostic immunoassay and binding protein tests based upon the Chemiluminescence Technology during the Term other than the assays identified and which are not improvements to such assays Licensor shall promptly and exclusively advise Licensee in writing of the availability of such assays and shall make available to Licensee all information in the possession of Licensor regarding such assays and shall give Licensee 120 days to make a proposal to Licensor whereby Licensee shall obtain licenses to make have made use and sell such assays Licensor shall accept or reject Licensees proposal.

License Property
The Licensor property was granted to Licensor by a University, the rights to the techniques for the measurement of the presence of antibodies, binding proteins and other analytes based upon the phenomenon of chemiluminescence.  The University inventions are specifically pertaining to Chemiluminescence Technology.

The technology is a proprietary technique for measurements based upon the phenomenon of chemiluminescence for which the University has applied for patent protection.

The Chemiluminescence technology is the body of knowledge inclusive of the Universitys Patent Rights and Proprietary Information relating to the quantification of substances utilizing light energy emissions resulting from reactions involving such substances that is useful in immunoassay and binding protein assay systems.

The Products are Clinical diagnostic kits and components of diagnostic kits the manufacture sale or use of which would constitute an infringement of the Universitys Patent rights but for the licenses granted hereby or which incorporate to a substantial degree technical Proprietary Information.

Field of Use
The field of use is measurement technology to clinical diagnostic immunoassay and binding protein assay systems developed.

IPSCIO Record ID: 237229

License Grant
The University of Wales grants to the Licensee, also of Wales, an exclusive right and license to develop manufacture market and sell either by itself or with such other parties as Licensee and Licensor shall determine clinical diagnostic kits and/or components thereof and/or any other related products incorporating the Chemiluminescence Technology covered by the Patents.
License Property
University has developed techniques for the measurement of the presence of antibodies binding proteins and other analytes based upon the phenomenon of chemiluminescence which it believes may be applicable to immunoassay binding protein and other assay systems.

The patents relate to Luminescent Protein Labelling, and, Homogeneous Assay.

Field of Use
Licensee has assisted in the development of the techniques and has a number of commercial contacts who would be interested in manufacturing and marketing clinical diagnostic kits components for such kits and other related products on a commercial scale and is also interested in manufacturing and marketing such kits and other products itself.

IPSCIO Record ID: 286052

License Grant
Licensor grants to a worldwide, nonexclusive, nontransferable right and license, with no right to grant any sublicenses, to make, have made, use, and sell Licensed products. Accordingly, the license includes the right of Licensee and purchasers of its Licensed products to practice methods covered by the Licensed patents and Licensed patent applications only by using such licensed products.
License Property
Licensor owns all rights to United States Patent titled Heterogenous chemiluminescent specific binding assay, and, its corresponding foreign-filed counterparts covering certain chemiluminescent specific binding assay methods and reagent systems.

Licensed Product shall mean a product for performing a Chemilumniescent Immunoassay only, and no other product, which when made, used, or sold would infringe a claim of a Licensed patent.

Chemilumniescent Immunoassay shall mean a liquid-phase heterogeneous chemiluminescent assay employing a chemiluminescent reactant as label and wherein the substance or condition to be determined, i.e., analyte of interest, is determined by binding thereto of an antibody or other specific binding protein.

Field of Use
Licensee intends to develop and market instruments and reagent systems for performing chemiluminescent immunoassays.

IPSCIO Record ID: 237230

License Grant
The University of Wales grants to the Licensee registered in England
– an exclusive license to use the Technical Information and under the Licensors copyright to use the Process to manufacture Products; and
– an exclusive license to use sell or otherwise deal in Products manufactured under the license anywhere in the Territory.

The Licensor hereby agrees to grant to the Licensee
– an exclusive license under the Patent Rights to use the Process to manufacture Products; and
– an exclusive license to use sell or otherwise deal in Products manufactured under the license anywhere in the Territory.

License Property
The Licensor has developed and is the beneficial owner of a substantial body of valuable Technical Information relating to the measurement of analytes based upon the phenomenon of chemiluminescence which is applicable to immunoassay binding protein and other assay systems and is the beneficial owner of the Patent Rights.

Process is the chemiluminescence technology and defined in the Patent Rights.

Products are clinical diagnostic kits and/or components thereof and/or any other products incorporating the Process.

Field of Use
The Licensee wishes to use such information and to work under the said Patent Rights in order to manufacture, use, sell or otherwise deal in the said chemiluminescence technology save and except the excluded uses.

IPSCIO Record ID: 329696

License Grant
Licensor of the United Kingdom grants a world-wide, exclusive sublicense under the University Patent Rights and a world-wide, exclusive license under the Licensor Patent Rights and Licensor Confidential Information to develop, use, manufacture, have manufactured, market and sell Licensed Products, and to practice the processes and procedures of such Patent Rights and Confidential Information.  The amendment further defines the licensed product.

Licensor shall disclose to Licensee all existing Chemiluminescence Technology which is necessary or in any way useful to enable Licensee to develop, use, manufacture, have manufactured, market and sell Licensed Products.  The Parties shall continue to negotiate in good faith a Development Agreement whereby Licensor shall assist Licensee in the development of Licensed Products.

License Property
Licensor has acquired the exclusive right and license to develop, manufacture, market and sell, either by itself or with such other parties as University and Licensor shall determine, clinical diagnosis kits and/or components thereof, and/or other related products, incorporating the University Technology covered by the University Patent Rights, with the right to grant sublicenses.

The licensed University technology consists of certain compounds, materials, processes, and procedures relating to the use of stable derivatives of aryl acridinium esters as labeling agents in chemiluminescent assays such that assay reagents may be labeled with such derivatives to very high densities, and such labeled assay reagents, following the triggering of a light emitting reaction, may be quantified or detected with high sensitivity by measuring or sensing the emitted light through simple photon counters.

Chemiluminescence Technology shall mean that body of knowledge inclusive of the Licensor Confidential Information and any and all knowledge now or hereafter disclosed in the University Patent Rights or Licensor Patent Rights.

Licensed Products shall mean products for the diagnosis, detection, prognosis or monitoring of infectious disease agents and the diagnosis, detection, prognosis or monitoring of oncogenes or various forms of cancer, which incorporate Licensor Confidential Information and/or subject matter within the scope of any valid claims of any patent in the University Patent Rights or the Licensor Patent Rights and utilize nucleic acid hybridization technology in such diagnosis, detection, prognosis or monitoring.

The patents relate to Luminescent Protein Labelling, Homogeneous Assay, Acridinium Label, and, Mass Photon Immunoassay.

The May 1989 amendment updates the Licensed Products to mean products for the diagnosis, detection, prognosis or monitoring of infectious disease agents, for the diagnosis, detection, prognosis or monitoring of oncogenes or various forms of cancer and for the detection or monitoring of levels of all bacteria as a screen for corrosion-causing microorganisms, through the use of probes to conserved sequences, in oilfield produced water and other specimens associated with the petroleum industry and use of petroleum products and for the detection or monitoring of two types of corrosion-causing microorganisms which have been isolated by British Petroleum (one of which is believed to be a member of the genus Desulfovibrio and the other of which is believed to be a member of the genus Desulfotomaculum, which incorporate Bioanalysis Confidential Information and/or subject matter within the scope of any valid claims of any patent in the University Patents Rights or the Licensor Patent Rights and utilize nucleic acid hybridization technology in such diagnosis, detection, prognosis or monitoring.

Field of Use
The field of use is nucleic acid hybridization technology, initially in the fields of infectious disease and oncogenes/cancer.

IPSCIO Record ID: 286050

License Grant
The Licensor of England grants a non-exclusive license, without sublicensing rights, under Licensed Patents to make, have made, use, and sell or otherwise dispose of Licensed Products bearing the name and trademark of Licensee prominently displayed thereon to End-Users, Authorized Distributors and Royalty-Bearing Distributors.
License Property
Licensor has the rights for the US patent titled Method of performing assay for analyte in liquid medium, as well as corresponding patents and patent applications applied for in the European Patent Office and in the United Kingdom, France, Germany, and Japan.

Class A Licensed Products shall mean any human, in vitro diagnostic immunoassay products, including but not limited to instruments, instrument kits, systems, assays or chemical products, but excluding assay products using genetic probe reagents or a combination of immunoassay reagents and genetic probe reagents, employing a labelled reagent to form a chemiluminescent label and another reagent which is bound to magnetically attractable particles, the manufacture, use or sale of which would, but for the license granted in Article II hereof, infringe one or more of the License Patents.

Class B Licensed Products shall mean any human, in vitro diagnostic genetic probe products, including but not limited to instruments, instrument kits, systems, assays, or chemical products,  including assay products using a combination of genetic probe reagents and immunoassay reagents, employing a labelled reagent to form a chemiluminescent label and another reagents which is bound to magnetically attractable particles, the manufacture, use or sale of which would, but for the license granted in Article II hereof, infringe one or more of the Licensed Patents.

Licensed Products shall mean Class A Licensed Products and Class B Licensed Products.

Field of Use
The field of use is for the conduct of human, in vitro diagnostic immunoassays and genetic probe assays for detection of an analyte in a human sample contained in a liquid medium characterized by the use of a labelled reagent which forms a chemiluminescent label system and another reagent bound to magnetically attractable particles.

IPSCIO Record ID: 306181

License Grant
For Biomarker IP, Licensor will grant an exclusive, perpetual, royalty-bearing license under Licensor Biomarker IP to make, have made, use, sell, offer for sale, import and otherwise exploit any and all Consumable Products, and have any and all of the foregoing performed on its behalf, in each case solely for applications other than developing and commercializing Clinical Laboratory Tests.  

This agreement has exclusive and non-exclusive territories.

License Property
Test Kit means a kit, biochip or other supply developed by Licensee pursuant to a Test Kit Development Program for an Application that corresponds to a Licensed Laboratory Test developed by Licensor and cleared or approved by the FDA or other Regulatory Authority, as relevant, for marketing in the applicable jurisdiction. A Test Kit will include components and instructions required for performing such Application.

Licensor is a leading provider of diagnostic testing, information and services and has substantial experience in the development and commercialization of products having Clinical Diagnostic Applications.

Test Kit Service means a clinical laboratory test that is performed by a member of the  Licensors Network or a Third Party using a Test Kit that has been approved or cleared by the FDA or other applicable Regulatory Authority for marketing in the applicable jurisdiction, if necessary, and has been developed by Licensee pursuant to a Test Kit Development Program.

Field of Use
This strategic alliance is to collaborate in the development and commercialization of proteomic diagnostic tests based on Licensee’s SELDI ProteinChip technology.

The ProteinChip Array technology is used for the discovery, validation, identification, and characterization of disease-associated proteins from biological samples. The versatile nature of this technology is enabling for a wide variety of applications in both research and clinical proteomics and will be reviewed in three application areas. A recent publication presents the use of the flexibility and power of the ProteinChip Array platform to elucidate the nature of novel protein inhibitors of HIV-1 replication, the molecules previously known as the CD8+ antiviral factors. Numerous cancer-related publications have demonstrated the discovery and development of biomarkers and multimarker patterns for protein-based predictive medicine.

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) represents the successful combination of retentate chromatography and mass spectrometry, and this technology is an integral part of Ciphergen's ProteinChip System, which was designed to answer biomedical questions by performing protein analyses on a single experimental platform. The quantification capability of the ProteinChip System is essential in all proteomic applications for which this technology is used. Here we describe methods and results for three short experiments mimicking realistic analytical challenges to provide practical examples of quantification.

Field means all potential Clinical Diagnostics.  Licensee develops, manufactures and markets its ProteinChip Systems using its patented surface enhanced laser desorption/ionization (SELDI) technology and also owns and operates a division directed toward the development and commercialization of products for the field of Clinical Diagnostics, including the discovery of disease-specific Biomarkers and protein signatures that could be utilized in Licensed Laboratory Tests and Test Kits.

Licensee develops, manufactures and sells ProteinChip Systems for life science researchers.  The systems consist of ProteinChip Readers, ProteinChip Software and related accessories, which are used in conjunction with consumable ProteinChip Arrays.  These products are sold primarily to biologists at pharmaceutical and biotechnology companies, and academic and government research laboratories.  The Company also provides research services primarily through its Biomarker Discovery Center® laboratories.

IPSCIO Record ID: 294268

License Grant
Licensor grants an exclusive, perpetual, worldwide license under all Licensor Biomarker IP, Licensor Collaboration IP and Licensor Platform IP to  use Instruments, and Proprietary Supplies supplied by Licensor solely to develop and commercialize such Licensed Laboratory Test; and, make, have made, use, sell, offer for sale, import and otherwise exploit any and all subject matter within the Licensor Licensed Technology that is not supplied to Licensee by Licensor hereunder or the applicable Supply Agreement or made generally commercially available to Third Parties by Licensor, in each case to develop and commercialize such Licensed Laboratory Test.

This agreement has exclusive and non-exclusive territories.

License Property
Licensor develops, manufactures and markets its Protein Chip Systems using its patented surface enhanced laser desorption/ionization (SELDI) technology and also owns and operates a division directed toward the development and commercialization of products for the field of Clinical Diagnostics, including the discovery, principally through Licensor Collaboration Agreements, of disease-specific Biomarkers and protein signatures that could be utilized in Licensed Laboratory Tests and Test Kits.

Clinical Diagnostic means, in connection with clinical medical practice, the assaying, testing, or determination outside of a living organism of one or more Biomarkers in or on any test sample for the purpose of identifying, characterizing, defining, or diagnosing a disease state or other condition in humans or animals, including without limitation determining the state of an individual’s health to treat or prevent disease as well as the screening, prognosis, therapeutic monitoring, and/or evaluation of the progression of any disease or other condition.

Biomarker means any
—  nucleic acid (whether DNA, RNA or otherwise), protein or organic molecule;
—  set of nucleic acids, proteins and/or organic molecules or
—  profile, i.e., presence and/or quantity, of the items described.  As used herein, the term protein refers to any polypeptide and the term nucleic acid refers to any nucleotide sequence, in either case whether naturally occurring, synthesized, modified or otherwise.

The patents relate to cancers and heart disease.

Field of Use
Field means all potential Clinical Diagnostics.   Licensor products are for the field of Clinical Diagnostics, including the discovery of disease-specific Biomarkers and protein signatures that could be utilized in Licensed Laboratory Tests and Test Kits .

Licensee is a provider of diagnostic testing, information and services and has substantial experience in the development and commercialization of products having Clinical Diagnostic Applications.  This alliances activities are directed toward discovery of Biomarkers for Clinical Diagnostic applications, and, modifications to the Licensors Platform Technology to meet the requirements of the Clinical Diagnostics markets and FDA.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.